|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01408732 |
|
Date of registration:
|
01/07/2011 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
|
|
Scientific title:
|
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia |
|
Date of first enrolment:
|
February 2011 |
|
Target sample size:
|
18 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01408732 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
Phase 1/Phase 2
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Holly Boyer, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Minnesota |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- a clinical diagnosis of HHT based on the Curacoa Criteria
- age 18 and older
- cognitive ability and willingness to sign the study consent form and complete the
study forms and questionnaires
Exclusion Criteria:
- previous sclerotherapy with Sodium Tetradecyl Sulfate
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Epistaxis
|
|
Hereditary Hemorrhagic Telangiectasia
|
|
Intervention(s)
|
|
Other: Standard Treatment
|
|
Drug: Sclerotherapy
|
|
Primary Outcome(s)
|
|
Severityof Epistaxis
[Time Frame: Change from Baseline to 14 weeks]
|
|
Secondary ID(s)
|
|
1101M95232
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|